BACKGROUND: Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous group of diseases with approximately 45 different causative genes described. The aims of this study were to determine the frequency of different genes in a large cohort of patients with CMT and devise guidelines for genetic testing in practice. METHODS: The genes known to cause CMT were sequenced in 1607 patients with CMT (425 patients attending an inherited neuropathy clinic and 1182 patients whose DNA was sent to the authors for genetic testing) to determine the proportion of different subtypes in a UK population. RESULTS: A molecular diagnosis was achieved in 62.6% of patients with CMT attending the inherited neuropathy clinic; in 80.4% of patients with CMT1 (demyelinating CMT) and in 25.2% of those with CMT2 (axonal CMT). Mutations or rearrangements in PMP22, GJB1, MPZ and MFN2 accounted for over 90% of the molecular diagnoses while mutations in all other genes tested were rare. CONCLUSION: Four commonly available genes account for over 90% of all CMT molecular diagnoses; a diagnostic algorithm is proposed based on these results for use in clinical practice. Any patient with CMT without a mutation in these four genes or with an unusual phenotype should be considered for referral for an expert opinion to maximise the chance of reaching a molecular diagnosis.
BACKGROUND:Charcot-Marie-Tooth disease (CMT) is a clinically and genetically heterogeneous group of diseases with approximately 45 different causative genes described. The aims of this study were to determine the frequency of different genes in a large cohort of patients with CMT and devise guidelines for genetic testing in practice. METHODS: The genes known to cause CMT were sequenced in 1607 patients with CMT (425 patients attending an inherited neuropathy clinic and 1182 patients whose DNA was sent to the authors for genetic testing) to determine the proportion of different subtypes in a UK population. RESULTS: A molecular diagnosis was achieved in 62.6% of patients with CMT attending the inherited neuropathy clinic; in 80.4% of patients with CMT1 (demyelinating CMT) and in 25.2% of those with CMT2 (axonal CMT). Mutations or rearrangements in PMP22, GJB1, MPZ and MFN2 accounted for over 90% of the molecular diagnoses while mutations in all other genes tested were rare. CONCLUSION: Four commonly available genes account for over 90% of all CMT molecular diagnoses; a diagnostic algorithm is proposed based on these results for use in clinical practice. Any patient with CMT without a mutation in these four genes or with an unusual phenotype should be considered for referral for an expert opinion to maximise the chance of reaching a molecular diagnosis.
Authors: Stephan Züchner; Irina V Mersiyanova; Maria Muglia; Nisrine Bissar-Tadmouri; Julie Rochelle; Elena L Dadali; Mario Zappia; Eva Nelis; Alessandra Patitucci; Jan Senderek; Yesim Parman; Oleg Evgrafov; Peter De Jonghe; Yuji Takahashi; Shoij Tsuji; Margaret A Pericak-Vance; Aldo Quattrone; Esra Battaloglu; Alexander V Polyakov; Vincent Timmerman; J Michael Schröder; Jeffery M Vance; Esra Battologlu Journal: Nat Genet Date: 2004-04-04 Impact factor: 38.330
Authors: M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly Journal: Neurology Date: 2005-04-12 Impact factor: 9.910
Authors: V Timmerman; P De Jonghe; C Ceuterick; E De Vriendt; A Löfgren; E Nelis; L E Warner; J R Lupski; J J Martin; C Van Broeckhoven Journal: Neurology Date: 1999-06-10 Impact factor: 9.910
Authors: E Nelis; C Van Broeckhoven; P De Jonghe; A Löfgren; A Vandenberghe; P Latour; E Le Guern; A Brice; M L Mostacciuolo; F Schiavon; F Palau; S Bort; M Upadhyaya; M Rocchi; N Archidiacono; P Mandich; E Bellone; K Silander; M L Savontaus; R Navon; H Goldberg-Stern; X Estivill; V Volpini; W Friedl; A Gal Journal: Eur J Hum Genet Date: 1996 Impact factor: 4.246
Authors: Craig L Bennett; Andrew J Shirk; Huy M Huynh; Valerie A Street; Eva Nelis; Lionel Van Maldergem; Peter De Jonghe; Albena Jordanova; Velina Guergueltcheva; Ivailo Tournev; Peter Van Den Bergh; Pavel Seeman; Radim Mazanec; Tomas Prochazka; Ivo Kremensky; Jana Haberlova; Michael D Weiss; Vincent Timmerman; Thomas D Bird; Phillip F Chance Journal: Ann Neurol Date: 2004-05 Impact factor: 10.422
Authors: Oleg V Evgrafov; Irena Mersiyanova; Joy Irobi; Ludo Van Den Bosch; Ines Dierick; Conrad L Leung; Olga Schagina; Nathalie Verpoorten; Katrien Van Impe; Valeriy Fedotov; Elena Dadali; Michaela Auer-Grumbach; Christian Windpassinger; Klaus Wagner; Zoran Mitrovic; David Hilton-Jones; Kevin Talbot; Jean-Jacques Martin; Natalia Vasserman; Svetlana Tverskaya; Alexander Polyakov; Ronald K H Liem; Jan Gettemans; Wim Robberecht; Peter De Jonghe; Vincent Timmerman Journal: Nat Genet Date: 2004-05-02 Impact factor: 38.330
Authors: José Berciano; Antonio García; Kristien Peeters; Elena Gallardo; Els De Vriendt; Ana L Pelayo-Negro; Jon Infante; Albena Jordanova Journal: J Neurol Date: 2015-04-01 Impact factor: 4.849
Authors: Rafael Sivera; Teresa Sevilla; Juan Jesús Vílchez; Dolores Martínez-Rubio; María José Chumillas; Juan Francisco Vázquez; Nuria Muelas; Luis Bataller; José María Millán; Fancesc Palau; Carmen Espinós Journal: Neurology Date: 2013-09-27 Impact factor: 9.910
Authors: Carly E Siskind; Seema Panchal; Corrine O Smith; Shawna M E Feely; Joline C Dalton; Alice B Schindler; Karen M Krajewski Journal: J Genet Couns Date: 2013-04-21 Impact factor: 2.537
Authors: Giorgia Bergamin; Francesca Boaretto; Chiara Briani; Elena Pegoraro; Mario Cacciavillani; Andrea Martinuzzi; Maria Muglia; Andrea Vettori; Giovanni Vazza; Maria Luisa Mostacciuolo Journal: Neuromolecular Med Date: 2014-05-13 Impact factor: 3.843